Key facts
- Cage Bio’s last known valuation is $125.0M (Jun 2019).
- It has raised $57.6M across 3 recorded rounds; the latest was Early Stage VC ($11.0M) in Apr 2024.
- Notable investors include Johnson & Johnson Innovation - JLABS, AG Collective Capital, CKG Management, HSC Next, MBC BioLabs — 6 tracked in total.
- Cage Bio has filed 5 Form Ds with the SEC since 2019, most recently Apr 2025 ($11.0M sold to 14 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Cage Bio
Funding rounds
3 roundsAbout Cage Bio
Developer of an eutectic ionic liquid designed to minimize the pervasive use of systemic drugs for the treatment of dermal diseases and symptoms. The company offers a product that is based on ionic liquid technology which offers broad-spectrum antimicrobial and anti-inflammatory properties along with enhancement of solubility and permeability, enabling physicians to treat dermal diseases successfully and effectively using effective products for dermatology.
- Sector
- Healthcare
- HQ
- San Carlos, CA, United States
- Employees
- 10
- Website
- cagebio.com/
- Ownership
- Privately Held (backing)
Cage Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cage Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cage Bio in its N-PORT filings yet. We sweep new filings monthly.